The 2026 DRC Ebola Outbreak: A Rare Strain, No Vaccine, and Warnings of a Hidden Crisis

An Ebola outbreak caused by the rare Bundibugyo virus is escalating in the eastern Democratic Republic of the Congo, and aid groups are warning that official case counts dramatically underrepresent its true scale. On June 1, 2026, the International Rescue Committee (IRC) stated the outbreak is likely "significantly larger and more advanced than official figures suggest," citing delayed detection and dangerously low levels of contact tracing in a region gripped by armed conflict .

Official case counts and the gap with reality

The latest official figures paint an incomplete picture. According to the DRC Ministry of Health's report from May 31, 2026, there were 282 confirmed cases and 42 confirmed deaths in the DRC, along with 220 suspected cases still under investigation . The Africa CDC, reporting through May 30, counted 263 confirmed cases and 43 confirmed deaths across the DRC and Uganda, with more than 1,100 suspected cases under investigation . The WHO's data through May 29 recorded 134 confirmed cases (nine of them in Uganda) and 18 confirmed deaths, while noting 906 suspected cases and 223 suspected deaths .

The combined total of suspected and confirmed cases reached roughly 1,262 cases and at least 241 deaths by May 29 . The stark difference between the confirmed and suspected figures—only about 12% of all reported cases had been laboratory-confirmed—exposes deep surveillance gaps in the outbreak zone .

This is the DRC's 17th Ebola outbreak since the virus was discovered in 1976, and it is already the third-largest Ebola outbreak on record overall . It comes just five months after the end of the country's previous outbreak .

The Bundibugyo strain: a rare virus with no countermeasures

This outbreak is driven by Bundibugyo virus (Orthoebolavirus bundibugyoense), a species first identified in Uganda in 2007 and distinct from the more common Zaire ebolavirus behind most previous outbreaks . This is only the third documented Bundibugyo outbreak, and it is by far the largest .

Crucially, no licensed vaccine or specific antiviral treatment is approved for the Bundibugyo strain. The existing Ervebo vaccine and other Ebola vaccines target Zaire ebolavirus and offer no protection against Bundibugyo . That gap has forced response teams to rely entirely on contact tracing, isolation, and supportive care—precisely the measures now failing.

Geographic spread: three DRC provinces and Uganda

The outbreak, which was first confirmed on May 15, 2026, has spread across three eastern DRC provinces: Ituri province remains the epicenter, with 264 of the country's 282 confirmed cases, but cases have also been reported in North Kivu (15 confirmed) and South Kivu (three confirmed) . Cross-border transmission has already occurred. Uganda has reported nine confirmed cases, including at least one death, with several linked to travel from Ituri .

The World Health Organization declared the outbreak a Public Health Emergency of International Concern on May 17, followed one day later by an Africa CDC declaration of a Public Health Emergency of Continental Security .

Warnings from aid groups: the response is being outpaced

On June 1, 2026, the International Rescue Committee (IRC) issued an urgent warning. Only about 20% of contacts are currently being traced, far below the 80–100% threshold needed to contain an Ebola outbreak . The virus may have been spreading undetected since before March—potentially three months before the first official case was identified . People are avoiding health facilities, and many individuals with Ebola symptoms are choosing to remain in the community .

Médecins Sans Frontières (MSF) has mobilized teams and is scaling up treatment and community engagement efforts, but the organization has indicated the response is being outpaced . The IRC has warned that without urgent international action, this could become the deadliest Ebola outbreak on record . A joint statement from the WHO and the Congolese government acknowledged "a challenging time," with health workers struggling to detect and isolate cases, trace contacts, and promote safe burials .

CEPI commits $60 million for vaccine development

In response to the absence of any approved countermeasure, the Coalition for Epidemic Preparedness Innovations (CEPI) announced on June 1, 2026, that it is committing approximately $60 million to accelerate the development of three vaccine candidates against Bundibugyo virus .

The largest share went to Moderna, which received $50 million to advance its mRNA-based Ebola Bundibugyo vaccine candidate through preclinical testing and Phase 1 clinical trials . An additional $8.6 million was allocated to a candidate from the University of Oxford and the Serum Institute of India, and $3.2 million to the International AIDS Vaccine Initiative (IAVI) . CEPI's head, Richard Hatchett, told Reuters it was possible to get vaccines ready for clinical trials within a couple of months, though the timeline depends on navigating the security situation in the outbreak zone .

Armed conflict and attacks on health infrastructure

The eastern DRC is an active conflict zone with multiple armed groups, and the security crisis is directly undermining the health response. Attacks on health facilities have been reported, and armed conflict has severely hampered contact tracing, community engagement, and the movement of medical personnel and supplies . The European Centre for Disease Prevention and Control (ECDC) has assessed the "complicated context" as a major factor driving the epidemiological uncertainty around the outbreak's true scope .

In this environment, the combination of a rare viral strain with no vaccine, minimal contact tracing, cross-border spread, and active conflict has created what aid groups describe as an exceptionally dangerous situation—one where official numbers may be describing only a fraction of the emergency unfolding on the ground.